RNAi Inhibition of Alpha-ENaC Expression
First Claim
Patent Images
1. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein:
- a. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8357 (SEQ ID NO;
145), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8357 (SEQ ID NO;
146);
orb. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8313 (SEQ ID NO;
57), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8313 (SEQ ID NO;
58);
orc. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8529 (SEQ ID NO;
361), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8529 (SEQ ID NO;
362);
ord. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8573 (SEQ ID NO;
449), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8573 (SEQ ID NO;
450).
4 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
-
Citations
21 Claims
-
1. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein:
-
a. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8357 (SEQ ID NO;
145), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8357 (SEQ ID NO;
146);
orb. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8313 (SEQ ID NO;
57), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8313 (SEQ ID NO;
58);
orc. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8529 (SEQ ID NO;
361), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8529 (SEQ ID NO;
362);
ord. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8573 (SEQ ID NO;
449), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8573 (SEQ ID NO;
450). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 19, 20, 21)
-
-
17. A composition comprising an iRNA agent to alpha-ENaC, wherein the iRNA agent comprises
a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the sense strand of an iRNA agent selected from the group consisting of ND8357 (SEQ ID NO: - 145), ND8313 (SEQ ID NO;
57), ND8529 (SEQ ID NO;
361), and ND8573 (SEQ ID NO;
449), andwherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the antisense strand of an iRNA agent selected from the group consisting of ND8357 (SEQ ID NO;
146), ND8313 (SEQ ID NO;
58), ND8529 (SEQ ID NO;
362), and ND8573 (SEQ ID NO;
450),the composition further comprising an epithelial receptor ligand. - View Dependent Claims (18)
- 145), ND8313 (SEQ ID NO;
Specification